ASKA Pharmaceutical Holdings
4886.TTSE PRIMEPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥71.1bn | ¥64.1bn | ¥62.8bn | ¥60.5bn | ¥56.6bn | — |
| Operating income | ¥5.8bn | ¥5.3bn | ¥6.5bn | ¥5.1bn | ¥4.8bn | — |
| Ordinary income | ¥5.7bn | ¥5.1bn | ¥6.5bn | ¥5.2bn | ¥4.9bn | — |
| Net income (owners) | ¥5.4bn | ¥5.1bn | ¥7.5bn | ¥4.2bn | ¥4.3bn | — |
| Total assets | ¥112.4bn | ¥104.3bnr | ¥90.7bn | ¥87.1bn | ¥83.3bn | — |
| Net assets / equity | ¥76.8bn | ¥71.8bnr | ¥61.9bn | ¥54.5bn | ¥48.9bn | ¥44.5bn |
| Operating cash flow | ¥6.3bn | ¥2.5bn | ¥1.5bn | ¥3.4bn | ¥2.8bn | — |
| EPS (basic) | ¥191.12 | ¥179.95 | ¥266.51 | ¥150.08 | ¥151.22 | — |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
6 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Animal Health Business | ¥7.3bn | ¥344m |
| Oversea Business | ¥4.6bn | ¥108m |
| Pharmaceutical Business | ¥58.9bn | ¥7.1bn |
| Other segments | ¥225m | −¥13m |
| Adjustments & eliminations | — | −¥1.7bn |
| Total | ¥71.1bn | ¥7.6bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.